Revelation Biosciences, Inc. (REVBW) stock
REVBWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVB
$0.01+0.00 (0.00%)
Close on Oct 30, 2026Market cap $16.05MP/E –Yield –
Revelation Biosciences total assets
Total assets on the balance sheet at the end of each period.
Revelation Biosciences's total assets was $12.50M at Jun 30, 2026. For fiscal 2025 it was $11.58M, up 74.9% from the year before. The highest annual figure on record is $74.16M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.58M | +74.9% |
| FY2024 | Dec 31, 2024 | $6.62M | -45.8% |
| FY2023 | Dec 31, 2023 | $12.21M | +121.9% |
| FY2022 | Dec 31, 2022 | $5.50M | +169.5% |
| FY2021 | Dec 31, 2021 | $2.04M | -97.2% |
| FY2020 | Dec 31, 2020 | $74.16M | +327023.7% |
| FY2019 | Dec 31, 2019 | $22.67K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.50M | +131.7% |
| Q1 FY2026 | Mar 31, 2026 | $15.04M | +278.9% |
| Q4 FY2025 | Dec 31, 2025 | $11.58M | +74.9% |
| Q3 FY2025 | Sep 30, 2025 | $12.86M | +90.7% |
| Q2 FY2025 | Jun 30, 2025 | $5.40M | -56.0% |
| Q1 FY2025 | Mar 31, 2025 | $3.97M | -73.0% |
| Q4 FY2024 | Dec 31, 2024 | $6.62M | -45.8% |
| Q3 FY2024 | Sep 30, 2024 | $6.74M | -52.6% |
| Q2 FY2024 | Jun 30, 2024 | $12.27M | -23.5% |
| Q1 FY2024 | Mar 31, 2024 | $14.70M | -18.9% |
| Q4 FY2023 | Dec 31, 2023 | $12.21M | +121.9% |
| Q3 FY2023 | Sep 30, 2023 | $14.22M | +115.4% |
| Q2 FY2023 | Jun 30, 2023 | $16.04M | +286.1% |
| Q1 FY2023 | Mar 31, 2023 | $18.12M | +127.1% |
| Q4 FY2022 | Dec 31, 2022 | $5.50M | +169.5% |
| Q3 FY2022 | Sep 30, 2022 | $6.60M | -91.0% |
| Q2 FY2022 | Jun 30, 2022 | $4.15M | -94.4% |
| Q1 FY2022 | Mar 31, 2022 | $7.98M | -89.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.04M | -97.2% |
| Q3 FY2021 | Sep 30, 2021 | $73.56M | +2002.2% |
| Q2 FY2021 | Jun 30, 2021 | $73.89M | +325815.1% |
| Q1 FY2021 | Mar 31, 2021 | $74.03M | – |
| Q4 FY2020 | Dec 31, 2020 | $74.16M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.50M | – |
| Q4 FY2019 | Dec 31, 2019 | $22.67K | – |